BLM: A Potential Drug Target and Biomarker for Blood Disorders

Target Name: BLM

NCBI ID: G641

Content of Review Report on BLM Target / Biomarker

BLM

BLM: A Potential Drug Target and Biomarker for Blood Disorders

BLM, or protein-like 3, is a molecule that has been identified as a potential drug target and biomarker for the treatment of blood disorders, including sickle cell anemia, myelodysplastic syndromes, and myeloma.

The BLM protein is a key regulator of hematopoietic stem cell (HSC) proliferation and differentiation, and is expressed in a variety of tissues and cells, including the bone marrow, where it plays a crucial role in the production of healthy red blood cells. In addition to its role in HSC biology, BLM has also been shown to play a key role in the regulation of immune cell function and cancer growth.

Several studies have suggested that BLM may be a promising drug target for the treatment of blood disorders due to its ability to regulate the production and function of healthy red blood cells. In addition, BLM has also been shown to be involved in the regulation of cancer cell growth and survival, which could make it an attractive target for the treatment of various types of cancer.

One of the key challenges in studying BLM as a drug target is its complex biology and the underlying mechanisms that regulate its function. However, research into BLM has identified several potential targets for drug development, including inhibition of its activity as a negative regulator of the erythropoietin gene, which is responsible for the production of red blood cells, and inhibition of its activity as a negative regulator of the Myb protein, which is involved in the regulation of cellular signaling pathways.

In addition to its potential as a drug target, BLM has also been identified as a potential biomarker for the diagnosis and monitoring of various types of blood disorders. The expression of BLM has been shown to be elevated in individuals with sickle cell anemia, a genetic disorder that affects the production of healthy red blood cells, and in individuals with myelodysplastic syndromes, a group of blood disorders that are characterized by the overproduction of certain blood cells.

In conclusion, BLM is a promising protein-like molecule that has the potential to be a drug target and biomarker for the treatment of blood disorders. Further research is needed to fully understand its biology and the underlying mechanisms that regulate its function, as well as to develop safe and effective treatments for the various types of blood disorders that it is involved in.

Protein Name: BLM RecQ Like Helicase

Functions: ATP-dependent DNA helicase that unwinds single- and double-stranded DNA in a 3'-5' direction (PubMed:9388193, PubMed:24816114, PubMed:25901030). Participates in DNA replication and repair (PubMed:12019152, PubMed:21325134, PubMed:23509288). Involved in 5'-end resection of DNA during double-strand break (DSB) repair: unwinds DNA and recruits DNA2 which mediates the cleavage of 5'-ssDNA (PubMed:21325134). Negatively regulates sister chromatid exchange (SCE) (PubMed:25901030). Stimulates DNA 4-way junction branch migration and DNA Holliday junction dissolution (PubMed:25901030). Binds single-stranded DNA (ssDNA), forked duplex DNA and DNA Holliday junction (PubMed:20639533, PubMed:24257077, PubMed:25901030). Recruited by the KHDC3L-OOEP scaffold to DNA replication forks where it is retained by TRIM25 ubiquitination, it thereby promotes the restart of stalled replication forks (By similarity)

The "BLM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BLM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets